Mainz Biomed Financials
MYNZ Stock | USD 6.65 0.32 4.59% |
Mainz |
Please note, the imprecision that can be found in Mainz Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mainz Biomed BV. Check Mainz Biomed's Beneish M Score to see the likelihood of Mainz Biomed's management manipulating its earnings.
Mainz Biomed Stock Summary
Mainz Biomed competes with Applied DNA, Neuronetics, Prenetics Global, Fonar, and MDxHealth. Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | NL0015000LC2 |
CUSIP | N5436L101 |
Location | Germany |
Business Address | Robert Koch Strasse |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | mainzbiomed.com |
Phone | 49 6131 554 2860 |
Currency | USD - US Dollar |
Mainz Biomed Key Financial Ratios
Return On Equity | -43.34 | ||||
Return On Asset | -0.99 | ||||
Target Price | 2.0 | ||||
Number Of Employees | 65 | ||||
Beta | 0.076 |
Mainz Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mainz Biomed's current stock value. Our valuation model uses many indicators to compare Mainz Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mainz Biomed competition to find correlations between indicators driving Mainz Biomed's intrinsic value. More Info.Mainz Biomed BV is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mainz Biomed's earnings, one of the primary drivers of an investment's value.Mainz Biomed BV Systematic Risk
Mainz Biomed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mainz Biomed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Mainz Biomed BV correlated with the market. If Beta is less than 0 Mainz Biomed generally moves in the opposite direction as compared to the market. If Mainz Biomed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mainz Biomed BV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mainz Biomed is generally in the same direction as the market. If Beta > 1 Mainz Biomed moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Mainz Biomed is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Mainz has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Mainz Biomed's financials are consistent with your investment objective using the following steps:- Review Mainz Biomed's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Mainz Biomed's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Mainz Biomed's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Mainz Biomed's stock is overvalued or undervalued.
Mainz Biomed December 9, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mainz Biomed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mainz Biomed BV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mainz Biomed BV based on widely used predictive technical indicators. In general, we focus on analyzing Mainz Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mainz Biomed's daily price indicators and compare them against related drivers.
Downside Deviation | 7.91 | |||
Information Ratio | 0.1179 | |||
Maximum Drawdown | 1007.24 | |||
Value At Risk | (10.71) | |||
Potential Upside | 19.05 |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.